EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
獨家報道：溫和肽類（GLP-1）減肥藥物可能成爲萬億美元市場，Tema etf 的首席執行官預測。
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.
根據Tema etf的創始人兼首席執行官Maurits Pot在接受Benzinga的獨家採訪時的樂觀預測，GLP-1類藥物肥胖治療市場預計將飆升至1萬億美元或更高。
"Our view is that in the long term, this is not a two-horse race between Eli Lilly Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO)," Maurits stated, challenging the prevailing notion of a duopoly in the weight-loss market.
"我們認爲，從長遠來看，這並不是伊利莎白・莉莉公司（NYSE:LLY）和諾和諾德有限公司（NYSE:NVO）之間的兩馬戲表演，" Maurits稱，挑戰了減肥市場壟斷的主流觀念。
Pot predicts that rising demand for weight loss treatments and expanded applications for GLP-1 drugs will drive this trillion-dollar market opportunity...
Pot預計，減肥治療需求和GLP-1藥物的擴...
登入免費觀看全文
登入/註冊